Encapsulated cell therapy-diabetes - AmCyte

Drug Profile

Encapsulated cell therapy-diabetes - AmCyte

Alternative Names: Encapsulated Islet Replacement - AmCyte

Latest Information Update: 01 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AmCyte
  • Developer Toronto General Hospital
  • Class Antihyperglycaemics; Cell therapies
  • Mechanism of Action Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 01 Aug 2007 ReNeuron acquires AmCyte
  • 01 Aug 2007 Discontinued - Phase-I/II for Diabetes mellitus in Canada (Intraperitoneal)
  • 09 Mar 2005 The first patient with type 1 diabetes mellituts has been transplanted with encapsulated islets without long-term immune suppression
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top